Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← BI 764198
reduces riskIncreased
risk →
reduces riskIncreased
risk →
BI 764198 for COVID-19
1
study with
129
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 BI 764198 studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← BI 764198
reduces riskIncreased risk → |
Apr 6 2023 |
et al., Thorax, doi:10.1136/thorax-2022-219668 | TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial |
| 117% higher mortality (p=0.18), 12% higher progression (p=0.84), and 42% worse recovery (p=0.48). RCT 129 hospitalized COVID-19 patients requiring non-invasive oxygen support showing no benefit and potential harm with BI 764198 (TRPC6 inhibitor). The study was terminated early due to lack of efficacy and an imbalance of fatal events (.. | ||
